The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Animals

This is a "connection" page, showing publications Mary Eileen Dolan has written about Animals.
Connection Strength

0.669
  1. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021 07; 14(4):1490-1504.
    View in: PubMed
    Score: 0.051
  2. Clinical translation of cell-based pharmacogenomic discovery. Clin Pharmacol Ther. 2012 Oct; 92(4):425-7.
    View in: PubMed
    Score: 0.028
  3. The emerging role of microRNAs in drug responses. Curr Opin Mol Ther. 2010 Dec; 12(6):695-702.
    View in: PubMed
    Score: 0.025
  4. Pharmacogenomic discovery using cell-based models. Pharmacol Rev. 2009 Dec; 61(4):413-29.
    View in: PubMed
    Score: 0.023
  5. Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. Mutagenesis. 2008 Sep; 23(5):341-6.
    View in: PubMed
    Score: 0.021
  6. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst). 2007 Aug 01; 6(8):1145-54.
    View in: PubMed
    Score: 0.019
  7. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 2007 May; 28(5):1111-6.
    View in: PubMed
    Score: 0.019
  8. Genomes as geography: using GIS technology to build interactive genome feature maps. BMC Bioinformatics. 2006 Sep 19; 7:416.
    View in: PubMed
    Score: 0.018
  9. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55.
    View in: PubMed
    Score: 0.017
  10. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother Pharmacol. 2003 Oct; 52(4):291-302.
    View in: PubMed
    Score: 0.015
  11. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther. 2003 Jul; 2(7):633-40.
    View in: PubMed
    Score: 0.015
  12. O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002 Sep; 1(11):943-8.
    View in: PubMed
    Score: 0.014
  13. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.014
  14. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7.
    View in: PubMed
    Score: 0.013
  15. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Mol Cancer Ther. 2001 Nov; 1(1):21-8.
    View in: PubMed
    Score: 0.013
  16. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice. Cancer Chemother Pharmacol. 2001; 47(1):63-9.
    View in: PubMed
    Score: 0.012
  17. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000 Oct 01; 60(19):5464-9.
    View in: PubMed
    Score: 0.012
  18. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9.
    View in: PubMed
    Score: 0.012
  19. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000; 46(2):150-5.
    View in: PubMed
    Score: 0.012
  20. Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res. 1999 Jul 01; 59(13):3059-63.
    View in: PubMed
    Score: 0.011
  21. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
    View in: PubMed
    Score: 0.011
  22. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs. 1998 Jun; 9(5):437-48.
    View in: PubMed
    Score: 0.010
  23. O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases. Biochem Pharmacol. 1998 May 15; 55(10):1701-9.
    View in: PubMed
    Score: 0.010
  24. Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol. 1998; 41(6):505-12.
    View in: PubMed
    Score: 0.010
  25. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
    View in: PubMed
    Score: 0.010
  26. Pharmacokinetics and metabolism in rats of 2,4-diamino-6-benzyloxy-5- nitrosopyrimidine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Drug Metab Dispos. 1996 Nov; 24(11):1205-11.
    View in: PubMed
    Score: 0.009
  27. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.009
  28. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemother Pharmacol. 1996; 37(6):569-73.
    View in: PubMed
    Score: 0.009
  29. Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995 Dec; 23(12):1394-9.
    View in: PubMed
    Score: 0.009
  30. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Drug Metab Dispos. 2015 Jul; 43(7):1084-90.
    View in: PubMed
    Score: 0.008
  31. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1994 Oct 01; 54(19):5123-30.
    View in: PubMed
    Score: 0.008
  32. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 1994 Sep 01; 54(17):4698-702.
    View in: PubMed
    Score: 0.008
  33. Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol. 1994; 35(2):121-6.
    View in: PubMed
    Score: 0.008
  34. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry. 1993 Nov 16; 32(45):11998-2006.
    View in: PubMed
    Score: 0.008
  35. Cell cycle arrest in a model of colistin nephrotoxicity. Physiol Genomics. 2013 Oct 01; 45(19):877-88.
    View in: PubMed
    Score: 0.007
  36. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993 Jul 20; 46(2):285-90.
    View in: PubMed
    Score: 0.007
  37. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(1):59-63.
    View in: PubMed
    Score: 0.007
  38. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993; 32(3):221-5.
    View in: PubMed
    Score: 0.007
  39. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
    View in: PubMed
    Score: 0.007
  40. Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):E2343-52.
    View in: PubMed
    Score: 0.007
  41. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 01; 52(5):1171-5.
    View in: PubMed
    Score: 0.007
  42. Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine. Carcinogenesis. 1991 Dec; 12(12):2305-9.
    View in: PubMed
    Score: 0.007
  43. Production of antibodies to peptide sequences present in human O6-alkylguanine-DNA alkyltransferase and their use to detect this protein in cell extracts. Carcinogenesis. 1991 Sep; 12(9):1671-7.
    View in: PubMed
    Score: 0.006
  44. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990; 2(11):371-7.
    View in: PubMed
    Score: 0.006
  45. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis. 1989 Sep; 10(9):1613-9.
    View in: PubMed
    Score: 0.006
  46. Intracellular activation of cytotoxic agents: kinetic models for methylnitrosoureas and N-methyl-N'-nitro-N-nitrosoguanidine in cell culture. Chem Res Toxicol. 1989 May-Jun; 2(3):157-61.
    View in: PubMed
    Score: 0.006
  47. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 01; 23(7):877-89.
    View in: PubMed
    Score: 0.005
  48. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8.
    View in: PubMed
    Score: 0.005
  49. Use of a dodecadeoxynucleotide to study repair of the O4-methylthymine lesion. Mutat Res. 1988 Mar; 193(2):131-7.
    View in: PubMed
    Score: 0.005
  50. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.005
  51. Properties and assay of mammalian O6-alkylguanine-DNA alkyltransferase. Pharmacol Ther. 1987; 34(2):167-79.
    View in: PubMed
    Score: 0.005
  52. Specificity of O6-alkylguanine-DNA alkyltransferase. IARC Sci Publ. 1987; (84):30-4.
    View in: PubMed
    Score: 0.005
  53. Extent of formation of O4-methylthymidine in calf thymus DNA methylated by N-methyl-N-nitrosourea and lack of repair of this product by rat liver O6-alkylguanine-DNA-alkyltransferase. Carcinogenesis. 1985 Nov; 6(11):1611-4.
    View in: PubMed
    Score: 0.004
  54. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005 Sep; 4(9):1364-8.
    View in: PubMed
    Score: 0.004
  55. Comparison of the rates of repair of O6-alkylguanines in DNA by rat liver and bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1984 Sep; 44(9):3806-11.
    View in: PubMed
    Score: 0.004
  56. 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Chem Res Toxicol. 2004 Sep; 17(9):1217-26.
    View in: PubMed
    Score: 0.004
  57. Comparison of repair of methylated pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli. Biochem Biophys Res Commun. 1984 Aug 30; 123(1):324-30.
    View in: PubMed
    Score: 0.004
  58. An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level. J Med Chem. 1983 Nov; 26(11):1656-9.
    View in: PubMed
    Score: 0.004
  59. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000 Nov 15; 60(22):6307-10.
    View in: PubMed
    Score: 0.003
  60. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000 Oct; 6(10):4154-7.
    View in: PubMed
    Score: 0.003
  61. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
    View in: PubMed
    Score: 0.003
  62. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemother Pharmacol. 2000; 45(6):437-40.
    View in: PubMed
    Score: 0.003
  63. Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Carcinogenesis. 1999 Dec; 20(12):2355-60.
    View in: PubMed
    Score: 0.003
  64. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des. 1999 Aug; 5(8):587-605.
    View in: PubMed
    Score: 0.003
  65. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother Pharmacol. 1999; 43(1):80-5.
    View in: PubMed
    Score: 0.003
  66. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1997; 39(4):307-16.
    View in: PubMed
    Score: 0.002
  67. Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol. 1996; 37(6):547-55.
    View in: PubMed
    Score: 0.002
  68. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995 Jul 01; 55(13):2853-7.
    View in: PubMed
    Score: 0.002
  69. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995; 51:167-223.
    View in: PubMed
    Score: 0.002
  70. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994 Nov 29; 48(11):2127-34.
    View in: PubMed
    Score: 0.002
  71. Metabolism and disposition of O6-benzyl-2'-deoxyguanosine in Sprague-Dawley rats. Chem Res Toxicol. 1994 Nov-Dec; 7(6):762-9.
    View in: PubMed
    Score: 0.002
  72. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res. 1994 Jul 01; 54(13):3487-93.
    View in: PubMed
    Score: 0.002
  73. Supplemental dietary calcium fails to alter the acute effects of 1,2-dimethylhydrazine on O6-methylguanine, O6-alkylguanine-DNA alkyltransferase and cellular proliferation in the rat colon. Carcinogenesis. 1993 Jun; 14(6):1175-9.
    View in: PubMed
    Score: 0.002
  74. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(6):471-6.
    View in: PubMed
    Score: 0.002
  75. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16; 84(24):1926-31.
    View in: PubMed
    Score: 0.002
  76. Cell specific differences in O6-methylguanine-DNA methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells. Carcinogenesis. 1988 Nov; 9(11):2053-8.
    View in: PubMed
    Score: 0.001
  77. Repair of O-alkylpyrimidines in mammalian cells: a present consensus. Proc Natl Acad Sci U S A. 1988 Mar; 85(6):1759-62.
    View in: PubMed
    Score: 0.001
  78. Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ Health Perspect. 1985 Oct; 62:109-14.
    View in: PubMed
    Score: 0.001
  79. Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and E. coli. Carcinogenesis. 1985 Jul; 6(7):1027-31.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.